Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer

The 12-month ctDNA detection rate was 27.3% (44/161). Seven patients relapsed without prior ctDNA detection. Of patients allocated to pembrolizumab, 23/32 (72%) already had metastatic disease on staging at the time of ctDNA detection. Only 5 patients started pembrolizumab; none achieved sustained ctDNA clearance, and 4 had recurred at analysis. In the observation group, median time to recurrence was 4.1 months. The therapeutic activity endpoint could not be assessed.

San Antonio Breast Cancer Symposium 2021PubMed 36423745